An Alabama resident is filed a Xarelto lawsuit against drug giants Bayer Pharmaceuticals and Janssen Pharmaceuticals over their blockbuster blood thinner Xarelto, claiming the anticoagulant caused life-threatening internal bleeding complications.

Plaintiff Veronica R. was first prescribed Xarelto in 2013, and had followed all medication instructions and listened to the advice of her physician. Despite her diligence, Veronica needed to seek medical attention on several occasions, with the most significant being on May 13, 2013.

Court documents indicate that Veronica suffered bleeding ulcers and vaginal bleeding, allegedly result of ingesting Xarelto. Veronica is filing this Xarelto bleeding lawsuit against Bayer and Janssen for failing to warn her against the potential dangers of Xarelto, and claims that she had no prior warning of the potential side effects before she suffered the bleeding events.

Additionally, her lawsuit indicates that her doctor also had no prior knowledge of this, and was not notified by the drug companies of possible Xarelto bleeding complication. Veronica insists that she never would have taken the blood thinner medication if she shad know the potential side effects associated with this drug, and would have opted for a safer product.

So for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, Veronica is suing Bayer and Janssen Pharmaceuticals. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.

Xarelto Bleeding Events

Xarelto is a new generation anticoagulant that contrasts greatly from America’s traditional blood thinner, Warfarin. Xarelto and the other newer anticoagulants, Pradaxa and Eliquis, are prescribed in one dose and do not require constant medical monitoring like Warfarin requires.

However, Warfarin patients have a key feature that Xarelto and other newer anticoagulants currently lack – a bleeding reversal agent. In the case of internal bleeding, patients implement vitamin K to stop any internal bleeding injury.

Xarelto was approved in 2011, and is often prescribed to treat patients with atrial fibrillation, and patients at high risk for stroke.

It was released as a joint effort between Bayer Pharmaceuticals and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Soon after the drug’s release, it soon dominated the anticoagulant market, but the companies were soon hit with numerous Xarelto injury claims.  Many Xarelto injury reports describe patients experiencing unexpected and uncontrollable bleeding eve

The Xarelto lawsuit is Case No. 2:15-cv-01567-EEF-MBN, in the U.S. District Court of Southern California.